Health Economics, IP & Early Access: Navigating Legal Grey Zones in the Race to Personalized Cancer Vaccines
Time: 3:00 pm
day: Conference Day Two
Details:
• How emerging legal frameworks like Montana’s Right To Try expansion could impact patient access to unapproved personalized vaccines – and what that means for regulatory strategy
• Balancing IP protection vs. platform flexibility in an era where proprietary algorithms, tumor-specific libraries and bioinformatic tools are central to value creation
• The role of patent exclusivity, trade secrets, and data protection in enabling commercial viability for PCVs – especially when facing fragmented regulatory landscapes
